Drug
PEG3350
PEG3350 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_4
2
67%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 42 (66.7%)
Trials by Status
recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
NCT06393400
completedphase_4
Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
NCT03742232
completedphase_4
A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children
NCT00583609
Clinical Trials (3)
Showing 3 of 3 trials
NCT06393400Phase 1
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
NCT03742232Phase 4
Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
NCT00583609Phase 4
A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3